22 unknown. 22 Phase 3, 8 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 22 | Unknown 22 |
| Phase 2 | 8 | Unknown 8 |
Follow Hyperlipidemias: new trials by email Literature Review of Hyperlipidemias trials Research Report on Hyperlipidemias
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Effects of Phytoestrogen From Pueraria Mirifica in Improvement of Serum Lipid Parameters in Postmenopausal Women Phytoestrogen, Diet control & life style modification - Dyslipidemias, Hypertriglyceridemia | Phase 2 / Phase 3 | Unknown | Dhurakij Pundit University | 10 | 2024-03-02 | 2024-05-24 |
| Xian-Hua-Cha for Relieving Hyperlipidemia With Obesity Xian-Hua-Cha - Hyperlipidemias, Obesity | Phase 3 | Unknown | Chang Gung Memorial Hospital | 100 | 2022-12-13 | 2024-10-08 |
| Efficacy and Safety of the Fixed-dose Combination Atorvastatin/Fenofibrate vs Atorvastatin in Patients With T2D and DLP. Atorvastatin 20 mg / Fenofibrate 160 mg in fixed dose, Atorvastatin (Lipitor ®) - Dyslipidemia Associated With Type II Diabetes Mellitus | Phase 3 | Unknown | Laboratorios Silanes S.A. de C.V. | 78 | 2022-02-15 | 2022-03-02 |
| Study of Long-Term Efficacy and Safety of LIB003 in CVD or High Risk for CVD Patients Needing Further LDL-C Reduction lerodalcibep, Placebo - Cardiovascular Risk Factor, Cardiovascular Diseases | Phase 3 | Unknown | LIB Therapeutics LLC | 900 | 2021-04-22 | 2023-12-11 |
| Evaluate the Efficacy and Safety of IBI306 in Subjects With Homozygous Familial Hypercholesterolemia IBI306 - Familial Hypercholesterolemia - Homozygous, Lipid Metabolism Disorders | Phase 2 / Phase 3 | Unknown | Shenzhen People's Hospital | 8 | 2019-11-05 | 2021-07-01 |
| Effects of Oral Glucose and Teduglutide on Plasma Lipoproteins TED + glucose - Hyperlipidemias | Phase 2 / Phase 3 | Unknown | University Health Network, Toronto | 15 | 2019-05-01 | 2021-04-29 |
| Study to Evaluate the Safety and Efficacy of CJ-30061 in Hypertensive Patients With Hyperlipidemia Amlodipine 10mg+Valsartan 160mg+Atorvastatin 40mg, Amlodipine 10mg+Valsartan 160mg, Valsartan 160mg+Atorvastatin 40mg - Hypertension, Hyperlipidemia | Phase 3 | Unknown | HK inno.N Corporation | 180 | 2017-10-13 | 2018-08-21 |
| A Comparative Study of Rosuvastatin and Atorvastatin in Patients With Hyperlipidemia Rosuvastatin, Atorvastatin - Hyperlipidemia | Phase 2 / Phase 3 | Unknown | Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh | 90 | 2016-09-01 | 2016-12-02 |
| Omega-3-Acid Ethyl Esters 90 Soft Capsules for Lowering Very High Triglycerides Omega-3-Acid Ethyl Esters 90 Soft Capsules, Corn Oil - Hypertriglyceridemia | Phase 3 | Unknown | Jiangsu HengRui Medicine Co., Ltd. | 240 | 2015-12-01 | 2015-12-09 |
| Evaluating the Efficacy and Safety of HCP1105 in Combined Hyperlipidemic Patients With High Risk for CHD HCP1105, HGP0816, Placebo of HCP1105 - Hyperlipidemias | Phase 3 | Unknown | Hanmi Pharmaceutical Company Limited | 270 | 2014-10-01 | 2015-09-16 |
| The Efficacy and Safety of a Combination Therapy of Rosuvastatin and Ezetimibe Versus Monotherapy of Rosuvastatin in Hypercholesterolemia Patients Rosuvastatin/Ezetimibe - Hypercholesterolemia | Phase 3 | Unknown | IlDong Pharmaceutical Co Ltd | 400 | 2014-07-01 | 2014-09-29 |
| Phase 3 Study to Evaluate the Efficacy and Safety of Omega-3-acids Ethylesters 90 in Type Ⅱb Hyperlipidemia Atorvastatin 20mg, Omega-3-acids ethylesters 90 4g, Placebo(Omega-3-acids ethylesters 90) - Hyperlipidemia, Familial Combined | Phase 3 | Unknown | Kuhnil Pharmaceutical Co., Ltd. | 80 | 2014-01-01 | 2014-03-20 |
| Efficacy and Safety of Fenofibrate Added on to Atorvastatin Compared With Atorvastatin Atorvastatin 20mg, Fenofibrate 160mg, Placebo (Fenofibrate 160 mg) - Mixed Hyperlipidemia | Phase 3 | Unknown | Chong Kun Dang Pharmaceutical | 476 | 2013-12-01 | 2015-02-04 |
| Efficacy and Safety of Telmisartan/Rosuvastatin Co-administration in Hypertensive Patients With Hyperlipidemia Telmisartan 80mg, Rosuvastatin 20mg, Rosuvastatin 10mg - Hypertension, Hyperlipidemia | Phase 3 | Unknown | IlDong Pharmaceutical Co Ltd | 310 | 2013-05-01 | 2014-03-14 |
| Efficacy and Safety of Kochujang Pills on Improvement of Blood Lipids Kochujang Pills, Placebo - Hyperlipidemia | Phase 2 / Phase 3 | Unknown | Chonbuk National University Hospital | 60 | 2012-11-01 | 2012-11-29 |
| The Effect of Extract of Green Tea on Obese Women and Obese Related Hormone Peptides EGCG(Epigallocatechin Gallate), Placebo - Diabetes Mellitus, Hyperlipidemia | Phase 2 / Phase 3 | Unknown | Taipei City Hospital | 92 | 2012-05-01 | 2014-05-26 |
| The Effects of Coenzyme A Combined With Statin on Serum Lipids in Patients With Hyperlipidemia Coenzyme A, Placebo - Hyperlipoproteinemia | Phase 2 / Phase 3 | Unknown | Zhejiang University | 320 | 2012-03-01 | 2013-08-23 |
| Efficacy and Safety Study of Pitavastatin and Atorvastatin in High Risk Hypercholesterolemic Patients Pitavastatin, Atorvastatin - Hyperlipidemia | Phase 3 | Unknown | Tai Tien Pharmaceuticals Co., Ltd. | 200 | 2011-07-01 | 2011-07-01 |
| Efficacy Study to Treat Subjects With Severe Hypertriglyceridemia AKR-963 - Severe Hypertriglyceridemia | Phase 3 | Unknown | Trygg Pharma, Inc. | 240 | 2010-10-01 | 2011-11-24 |
| The Effect of Niacin Administration on Oxidative Stress in Patients With Hypercholesterolmia, as Measured by the Use of a Novel Biomarker Niacin\Laropiprant - Hypercholesterolemia | Phase 3 | Unknown | Rambam Health Care Campus | 30 | 2010-04-01 | 2010-03-01 |
Showing 20 of 22. Sign in to see all of them.
Hypercholesterolemia (4) · Hypertriglyceridemia (4) · Dyslipidemias (2) · Hypertension (2) · Cardiovascular Diseases (1) · Diabetes Mellitus (1) · Diabetes Mellitus, Type 2 (1) · Homozygous Familial Hypercholesterolemia (1) · Hyperlipidemia, Familial Combined (1) · Hyperlipoproteinemia Type I (1) · Hyperlipoproteinemia Type II (1) · Hyperlipoproteinemias (1) · Lipid Metabolism Disorders (1) · Myocardial Infarction (1)
Metabolic Diseases (22) · Nutritional and Metabolic Diseases (22) · Lipid Metabolism Disorders (21) · Dyslipidemias (20) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (4) · Genetic Diseases, Inborn (4) · Lipid Metabolism, Inborn Errors (4) · Metabolism, Inborn Errors (4) · Hyperlipoproteinemias (3) · Vascular Diseases (3) · Cardiovascular Diseases (2) · Endocrine System Diseases (2) · Glucose Metabolism Disorders (2) · Pathological Conditions, Signs and Symptoms (2)
Atorvastatin (6) · Rosuvastatin Calcium (3) · Fenofibrate (2) · Alipogene tiparvovec (1) · Amlodipine (1) · Cellulose (1) · Coenzyme A (1) · Corn Oil (1) · Cyclosporine (1) · Ezetimibe (1) · Glucose (1) · Mycophenolic Acid (1) · Phytoestrogens (1) · Tea (1) · Telmisartan (1)
IlDong Pharmaceutical Co Ltd (2) · Amsterdam Molecular Therapeutics (1) · Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh (1) · Chang Gung Memorial Hospital (1) · China Medical University Hospital (1) · Chonbuk National University Hospital (1) · Chong Kun Dang Pharmaceutical (1) · Dhurakij Pundit University (1) · HK inno.N Corporation (1) · Hanmi Pharmaceutical Company Limited (1) · Jiangsu HengRui Medicine Co., Ltd. (1) · Kuhnil Pharmaceutical Co., Ltd. (1) · LIB Therapeutics LLC (1) · Laboratorios Silanes S.A. de C.V. (1) · Rambam Health Care Campus (1)
South Korea (7) · Taiwan (4) · Canada (2) · China (2) · Israel (2) · United States (2) · Bangladesh (1) · India (1) · Mexico (1) · Thailand (1)
Chia-I Tsai, V.S (1) · Chung-Hua Hsu, PHD (1) · Duk-Hyun Kang, Ph.D (1) · Evan A Stein, MD PhD (1) · Francisco G Padilla Padilla, M.D (1) · Hee Kyoung Cheon, Ph.D. (1) · Hong Seog Seo, Ph.D. (1) · Jaw-Wen Chen, M.D. Ph.D. (1) · Juan A Peraza Zaldivar, M.D (1) · Jung-yeol Park, M.D., Ph.D. (1) · Junzhu Chen (1) · Kevin C Maki, PhD (1) · Liz Phima (1)
PMID 18468736, PMID 22717743, PMID 24098467, PMID 24382338, PMID 25027585, PMID 26093535, PMID 38958989, PMID 40323331